Concerning mTOR inhibition, Huye et al. created rapamycin resistant anti-CD19 CAR T-cells and found out that those had an increased antitumor activity in Burkitt’s lymphoma and ALL cell lines [77]. Here, CD19 is linked to acute lymphoblastic leukemia.